Current advances in development of new docetaxel formulations
文献类型：期刊论文
| 作者 | Zhang, Enhui1,2,3 ; Xing, Ronge1,2,3; Liu, Song1,2,3; Li, Pengcheng1,2,3
|
| 刊名 | EXPERT OPINION ON DRUG DELIVERY
 |
| 出版日期 | 2019-03-04 |
| 卷号 | 16期号:3页码:301-312 |
| ISSN号 | 1742-5247 |
| 关键词 | Docetaxel drug delivery system targeting liposome nanoparticle |
| DOI | 10.1080/17425247.2019.1583644 |
| 通讯作者 | Xing, Ronge(xingronge@qdio.ac.cn) ; Li, Pengcheng(pcli@qdio.ac.cn) |
| 英文摘要 | Introduction: Docetaxel (DTX) is one of the most important chemotherapeutic agents and has been widely used for treatment of various types of cancers. However, the clinical chemotherapy of DTX gives many undesirable side effects due to the usage of organic solvent in the injection and its low selectivity for tumor cells. With the evolution of pharmaceutical technologies, great efforts have been paid to develop new DTX formulations to overcome these problems. Areas covered: This review provided an overview of the preparation and activities of new DTX formulations, which were classified by administration methods, including injection, oral, transdermal and rectal administration. Besides, up to date information of the clinical status of new DTX formulations was summarized. We also discussed the challenges and perspectives of the future development of DTX formulations. Expert opinion: There have been numerous studies on new DTX-based formulations in recent years, and many of them exhibited significantly enhanced anti-tumor and targeting activity compared with DTX in preclinical studies. However, only a few entered clinical trials, and none has been approved into market. The clinical translation of experimental drug faces many hurdles, including the limited knowledge of nanomedicine and oncology, safety issues, controllable and reproducible production. |
| 资助项目 | National Key R&D Program of China[2018YFC0311305] ; Special projects of Foshan science and technology innovation team[2017IT100054] |
| WOS研究方向 | Pharmacology & Pharmacy |
| 语种 | 英语 |
| 出版者 | TAYLOR & FRANCIS LTD |
| WOS记录号 | WOS:000461429100009 |
| 源URL | [http://ir.qdio.ac.cn/handle/337002/155223]  |
| 专题 | 海洋研究所_实验海洋生物学重点实验室 |
| 通讯作者 | Xing, Ronge; Li, Pengcheng |
| 作者单位 | 1.Chinese Acad Sci, Inst Oceanol, CAS Key Lab Expt Marine Biol, Qingdao, Peoples R China 2.Qingdao Natl Lab Marine Sci & Technol, Lab Marine Drugs & Bioprod, Qingdao, Peoples R China 3.Chinese Acad Sci, Ctr Ocean Mega Sci, Qingdao, Peoples R China |
| 推荐引用方式 GB/T 7714 | Zhang, Enhui,Xing, Ronge,Liu, Song,et al. Current advances in development of new docetaxel formulations[J]. EXPERT OPINION ON DRUG DELIVERY,2019,16(3):301-312. |
| APA | Zhang, Enhui,Xing, Ronge,Liu, Song,&Li, Pengcheng.(2019).Current advances in development of new docetaxel formulations.EXPERT OPINION ON DRUG DELIVERY,16(3),301-312. |
| MLA | Zhang, Enhui,et al."Current advances in development of new docetaxel formulations".EXPERT OPINION ON DRUG DELIVERY 16.3(2019):301-312. |
入库方式： OAI收割
来源：海洋研究所
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。